Cohance Lifesciences Limited (BOM:543064)
405.75
-8.25 (-1.99%)
At close: Jun 19, 2026
Cohance Lifesciences Revenue
In the fiscal year ending March 31, 2026, Cohance Lifesciences had annual revenue of 22.69B INR, down -13.03%. Cohance Lifesciences had revenue of 6.19B in the quarter ending March 31, 2026, a decrease of -26.33%.
Revenue
22.69B
Revenue Growth
-13.03%
P/S Ratio
6.83
Revenue / Employee
18.72M
Employees
1,212
Market Cap
155.04B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 22.69B | -3.40B | -13.03% |
| Mar 31, 2025 | 26.09B | 15.57B | 148.11% |
| Mar 31, 2024 | 10.51B | -2.89B | -21.56% |
| Mar 31, 2023 | 13.40B | 201.07M | 1.52% |
| Mar 31, 2022 | 13.20B | 3.11B | 30.75% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jubilant Pharmova | 82.80B |
| Granules India | 53.66B |
| J. B. Chemicals & Pharmaceuticals | 41.48B |
| Viyash Scientific | 34.20B |
| AstraZeneca Pharma India | 22.76B |
| Caplin Point Laboratories | 21.87B |
| FDC Limited | 21.71B |
| Sanofi India | 17.74B |
Cohance Lifesciences News
- 5 weeks ago - Cohance Lifesciences Transcript: Q4 25/26 - Transcripts
- 5 weeks ago - Cohance Lifesciences Quarterly report: Q4 2026 - Filings
- 5 weeks ago - Cohance Lifesciences Slides: Q4 2026 - Filings
- 4 months ago - Cohance Lifesciences Transcript: Q3 25/26 - Transcripts
- 4 months ago - Cohance Lifesciences Quarterly report: Q3 2026 - Filings
- 4 months ago - Cohance Lifesciences Slides: Q3 2026 - Filings
- 7 months ago - Cohance Lifesciences Transcript: Q2 25/26 - Transcripts
- 7 months ago - Cohance Lifesciences Quarterly report: Q2 2026 - Filings